Why do cgm require a prescription

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Continuous glucose monitors (CGMs) require prescriptions primarily because they are classified as Class II medical devices by the FDA, requiring professional oversight for safe use. This classification stems from their role in managing diabetes, where incorrect readings could lead to dangerous treatment decisions. The FDA first cleared CGMs for prescription use in 1999, with Dexcom's STS system being among the earliest approved. Prescriptions ensure proper patient selection, training, and integration with insulin therapy, particularly for the 37.3 million Americans with diabetes who might benefit from these devices.

Key Facts

CGMs are FDA Class II medical devices requiring prescription due to potential risks if used incorrectly
First FDA clearance for prescription CGMs occurred in 1999 with devices like Dexcom's STS system
Approximately 37.3 million Americans have diabetes (CDC 2022 data), representing the primary user population
Prescriptions ensure proper patient training and integration with insulin therapy protocols
Insurance coverage for CGMs typically requires documented medical necessity through prescription

Overview

Continuous glucose monitors (CGMs) emerged in the late 1990s as revolutionary tools for diabetes management, transforming how patients track blood sugar levels. Unlike traditional fingerstick glucose meters that provide single-point measurements, CGMs offer real-time, continuous data through subcutaneous sensors typically worn for 7-14 days. The regulatory landscape for these devices developed alongside their technological evolution. The FDA classified CGMs as Class II medical devices under 21 CFR 862.1355, a category requiring prescription oversight due to their "moderate to high risk" nature when used for medical decision-making. This classification reflects concerns about potential harm from inaccurate readings—studies show even 20% error rates in glucose measurements could lead to dangerous insulin dosing errors. The prescription requirement aligns with medical device regulations established through the 1976 Medical Device Amendments to the Food, Drug, and Cosmetic Act, which created the three-tier classification system still used today.

How It Works

The prescription process for CGMs involves multiple steps ensuring appropriate use. First, healthcare providers assess patient eligibility based on factors like diabetes type, treatment regimen, and hypoglycemia risk. For Type 1 diabetes patients (approximately 5-10% of diabetes cases), CGMs are often prescribed alongside insulin pumps as part of automated insulin delivery systems. The prescription itself specifies device type, sensor duration, and calibration requirements. Medical necessity documentation must demonstrate factors like frequent hypoglycemia, hypoglycemia unawareness, or suboptimal glycemic control (typically A1C >7%). Insurance approval frequently requires this documentation, with Medicare covering CGMs for beneficiaries with intensive insulin therapy since 2017. Providers also provide training on insertion techniques, data interpretation, and alarm management—critical components since studies show proper training reduces severe hypoglycemia events by up to 40%.

Why It Matters

The prescription requirement for CGMs has significant real-world implications for diabetes care and healthcare systems. By ensuring professional oversight, it helps prevent adverse events—research indicates properly managed CGM use reduces severe hypoglycemia by 72% and hyperglycemia by 43% compared to standard monitoring. This translates to substantial healthcare savings, as severe hypoglycemia events cost approximately $1,288 per emergency department visit. The system also addresses health disparities by requiring providers to consider individual patient needs and capabilities. Looking forward, regulatory agencies are evaluating prescription requirements as technology evolves, with the FDA granting some over-the-counter approvals for non-adjunctive devices in 2023, potentially expanding access while maintaining safety standards for medical-decision devices.